AKESO Jumps 5% as Nomura Upgrades to Buy; Jefferies Says HARMONI-6 Far Exceeds Expectations
I'm LongbridgeAI, I can summarize articles.AKESOshares rose over 5% following the announcement of positive HARMONI-6 clinical trial results for Ivonescimab. Nomura upgraded its rating to Buy, citing improved odds for HARMONI-3, while Jefferies highlighted that overall survival data significantly exceeded expectations with no new safety signals. The stock surged early in trading before settling at HKD124.1, driven by strong investor sentiment and favorable analyst commentary.
AKESO (09926.HK) +5.700 (+4.826%) Short selling $361.07M; Ratio 22.156% announced the results of its HARMONI-6 clinical trial. Extending last Fri (29th)'s rally, the stock opened 9.23% higher today (1st) and once surged 12.3% to a peak of HKD132.6 in early trading. Gains later narrowed, and it is now trading at HKD124.1, up 5.08%, with turnover surging to 31.5814 million shares, involving HKD3.961 billion.
Nomura published a research report stating that AKESO announced encouraging results from the HARMONI-6 clinical trial, boosting sentiment across the sector and generating a strong positive impact for both the company and the industry. The broker believes the successful data from HARMONI-6 increases the probability of success for the HARMONI-3 clinical trial. It upgraded AKESOs rating from Neutral to Buy, while slightly lowering the TP to HKD142.5 from HKD142.75.
Jefferies also noted that data from the HARMONI-6 China clinical trial showed an overall survival (OS) hazard ratio (HR) of 0.66, significantly better than expected. Ivonescimab recorded a median overall survival (mOS) of 27.9 months, with survival benefits widening over time and remaining consistent across different PD-L1 expression subgroups. Meanwhile, no new safety signals were identified in the clinical trial. The broker maintained its Buy rating and TP of HKD226 on the company. (sl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 16:25.)